Maravai LifeSciences Securities Fraud Lawsuits
Analysis based on 41 articles · First reported Mar 04, 2025 · Last updated Apr 07, 2025
The class action lawsuits against Maravai LifeSciences Holdings, alleging securities fraud due to financial reporting issues, have led to a significant drop in the company's stock price. This event highlights the importance of robust internal controls and accurate financial reporting for publicly traded companies, potentially increasing scrutiny on similar firms in the biotechnology sector.
Maravai LifeSciences Holdings is facing multiple class action lawsuits filed by law firms including Levi & Korsinsky, The Gross Law Firm, and Robbins Geller Rudman & Dowd LLP. These lawsuits allege securities fraud, claiming that Maravai LifeSciences Holdings made false and misleading statements by failing to disclose inadequate internal controls over financial reporting, inaccurate revenue recognition on certain 2024 transactions, and overstated goodwill. The company's stock price fell nearly 22% after it announced the postponement of its fiscal 2024 earnings release and delayed its annual report filing, citing issues related to a potential non-cash impairment charge for goodwill from its Alphazyme LLC acquisition, a $3.9 million revenue recognition error, and material weaknesses in its internal controls. Investors who suffered losses during the class period of August 7, 2024, to February 24, 2025, have until May 5, 2025, to seek appointment as lead plaintiff.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard